SPCC1235.18 Antibody

What is SPCC1235.18 antibody and what organism does it target?

SPCC1235.18 antibody is a research reagent used to detect and analyze the SPCC1235.18 protein in Schizosaccharomyces pombe (fission yeast). The antibody is typically derived through immunization protocols using recombinant protein or synthetic peptides corresponding to specific regions of the SPCC1235.18 protein. Similar to other S. pombe antibodies like SPCC1235.17, these research tools are critical for investigating protein expression, localization, and function in yeast models, which serve as important eukaryotic model organisms for understanding fundamental cellular processes .

What applications are suitable for SPCC1235.18 antibody in research?

While specific application data for SPCC1235.18 antibody may vary between manufacturers, most S. pombe antibodies like SPCC1235.17 are validated for Western blotting (WB) and ELISA applications . Based on antibody engineering principles, researchers can optimize protocols for immunofluorescence (IF), immunohistochemistry (IHC), and immunoprecipitation (IP) with proper validation. The antibody's specificity for recognizing native versus denatured protein conformations will determine its utility across these applications, with antibodies recognizing linear epitopes typically performing better in Western blotting, while those recognizing conformational epitopes may be more suitable for IP and live-cell applications .

What storage and handling conditions preserve SPCC1235.18 antibody activity?

For optimal preservation of antibody activity, SPCC1235.18 antibody should be stored at -20°C or -80°C, similar to other research antibodies for S. pombe proteins . For working stocks, aliquoting is recommended to avoid repeated freeze-thaw cycles that can compromise antibody binding capacity. When handling the antibody for experiments, it should be kept on ice or at 4°C, and exposure to direct light should be minimized, especially if the antibody is fluorescently labeled. Standard buffer compositions typically include preservatives such as sodium azide (0.09%) and stabilizers like BSA (0.2%) to maintain antibody integrity during storage .

How should I determine the optimal dilution for SPCC1235.18 antibody in Western blotting experiments?

To determine the optimal working dilution for SPCC1235.18 antibody in Western blotting, a systematic titration approach is recommended:

• Start with a broad range dilution series (e.g., 1:500, 1:1000, 1:2000, 1:5000) using consistent protein loading (20-30 μg total protein per lane).

• Include positive controls (purified antigen or known expressing samples) and negative controls (pre-immune serum at 1:1000 dilution) .

• Evaluate signal-to-noise ratio, background levels, and specificity of band detection.

• Perform secondary titrations around the most promising dilution to fine-tune conditions.

Antibody performance depends on multiple factors including the abundance of target protein, sample preparation methods, and detection system sensitivity. The dilution that produces strong specific signal with minimal background should be selected for research applications .

What controls are essential when validating SPCC1235.18 antibody specificity?

Rigorous validation of SPCC1235.18 antibody specificity requires multiple types of controls:

These controls collectively provide evidence for antibody specificity and should be documented in research publications to substantiate the validity of experimental findings .

What immunoprecipitation protocol modifications are needed for SPCC1235.18 in yeast cells?

When performing immunoprecipitation with SPCC1235.18 antibody in yeast cells, several modifications to standard mammalian cell protocols are necessary:

• Cell disruption requires more aggressive methods due to the rigid yeast cell wall - typically using glass bead lysis in buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and protease inhibitors.

• Pre-clearing with Protein A/G beads should be extended to 2 hours to reduce non-specific binding, which is often higher with yeast lysates.

• Antibody incubation may require optimization beyond the typical 1:50-1:100 dilution range, with extended incubation times (overnight at 4°C) to improve pull-down efficiency.

• Washing stringency often needs adjustment, with additional high-salt washes (300-500 mM NaCl) to reduce background while preserving specific interactions.

• Detection methods should account for potential cross-reactivity with highly abundant yeast proteins by using competing peptides as additional controls .

How do I address non-specific binding when using SPCC1235.18 antibody in immunofluorescence?

Non-specific binding in immunofluorescence with SPCC1235.18 antibody can be addressed through a systematic optimization approach:

• Increase blocking stringency using combinations of BSA (3-5%), normal serum from the secondary antibody species (5-10%), and non-ionic detergents (0.1-0.3% Triton X-100).

• Optimize fixation protocols - excessive cross-linking with formaldehyde can create artificial epitopes leading to non-specific binding. Test shorter fixation times or alternative fixatives like methanol.

• Implement epitope retrieval protocols if necessary, starting with citrate buffer (pH 6.0) heating methods and titrating exposure times.

• Increase antibody specificity by pre-absorbing with total yeast lysate from strains lacking the SPCC1235.18 protein to remove antibodies recognizing common yeast epitopes.

• Validate specificity using peptide competition assays where pre-incubation of the antibody with excess immunizing peptide should abolish specific staining patterns while non-specific binding often remains .

What factors affect the reproducibility of SPCC1235.18 antibody in quantitative analyses?

Multiple factors can impact the reproducibility of SPCC1235.18 antibody in quantitative analyses:

• Antibody lot-to-lot variation: Even affinity-purified antibodies may show batch-to-batch differences in epitope recognition and binding affinity. Maintaining detailed records of antibody source, lot number, and performance characteristics is essential.

• Sample preparation consistency: Variations in cell lysis efficiency, protein extraction protocols, and buffer compositions can significantly alter epitope accessibility and antibody binding kinetics.

• Normalization strategy: Selection of appropriate loading controls that remain stable under experimental conditions is critical for accurate quantification.

• Detection system linearity: The dynamic range of detection methods (chemiluminescence, fluorescence) must be established to ensure quantitative measurements remain within the linear response range.

• Analysis methodology: Image acquisition settings, software algorithms, and background subtraction methods should be standardized across experimental replicates.

To maximize reproducibility, researchers should develop standard operating procedures that define acceptable performance parameters and include positive controls at multiple dilutions to calibrate each experimental run .

How can conformational epitopes in SPCC1235.18 affect antibody performance across different applications?

The three-dimensional structure of epitopes in SPCC1235.18 can significantly impact antibody performance across research applications:

• Linear versus conformational epitopes: Antibodies recognizing linear epitopes typically perform better in applications where proteins are denatured (Western blot), while those recognizing conformational epitopes excel in applications maintaining native protein structure (IP, IF) .

• Application compatibility matrix:

• Denaturing versus native conditions: The buffer composition, detergents, reducing agents, and sample preparation methods can preserve or disrupt epitope conformation, directly impacting antibody binding.

• Post-translational modifications: Phosphorylation, glycosylation, or other modifications near the epitope region can sterically hinder antibody access or alter epitope conformation in an application-specific manner.

Understanding the nature of the epitope recognized by SPCC1235.18 antibody allows researchers to predict performance limitations and develop appropriate validation strategies for each experimental context .

How can I optimize chromatin immunoprecipitation (ChIP) protocols for SPCC1235.18 antibody in yeast?

Optimizing ChIP protocols for SPCC1235.18 antibody in yeast requires several specific modifications:

• Crosslinking optimization: For yeast cells, formaldehyde concentration should be increased to 1.5-2% with extended crosslinking times (15-20 minutes) to overcome reduced cell permeability due to the cell wall.

• Cell disruption: Mechanical disruption using glass beads is essential for efficient chromatin preparation from yeast cells, typically requiring 6-8 cycles of vortexing (30 seconds) with cooling intervals.

• Sonication parameters: Due to differences in yeast chromatin organization, sonication conditions should be optimized to achieve DNA fragments of 200-500 bp, typically requiring more aggressive conditions than mammalian samples.

• Antibody selection: For ChIP applications, antibodies recognizing native protein conformations are preferred. Pre-validation using immunoprecipitation under native conditions can predict ChIP performance.

• Specificity controls: Include matched IgG controls from the same species as the primary antibody and test specificity in strains with tagged versions of SPCC1235.18 using tag-specific antibodies as positive controls.

These protocol adaptations address the unique challenges of performing ChIP with yeast samples while maintaining the specificity and efficiency required for chromatin interaction studies .

What strategies can address epitope masking in protein complex studies with SPCC1235.18 antibody?

When investigating protein complexes containing SPCC1235.18, epitope masking can compromise antibody accessibility and binding. Several strategies can address this challenge:

• Multiple antibody approach: Develop and validate antibodies targeting different epitopes within SPCC1235.18 to increase the probability of recognizing accessible regions in complexes.

• Mild denaturation techniques: Employ controlled partial denaturation conditions using low concentrations of urea (1-2 M) or mild detergents (0.1% SDS) that may expose masked epitopes without completely disrupting complex architecture.

• Crosslinking strategies: Implement variable-length crosslinkers to stabilize complexes while maintaining antibody accessibility to specific epitopes.

• Epitope-tagged protein expression: Generate strains expressing epitope-tagged versions of SPCC1235.18 (HA, FLAG, Myc) positioned at locations less likely to interfere with complex formation.

• Proximity labeling approaches: Use BioID or APEX2 fusion proteins to identify interaction partners without relying on direct antibody binding to complexes.

By employing these complementary approaches, researchers can overcome epitope masking challenges that often complicate antibody-based studies of protein complexes in their native states .

How does phosphorylation status affect SPCC1235.18 antibody recognition in cell cycle studies?

The phosphorylation status of SPCC1235.18 can significantly impact antibody recognition in cell cycle studies, requiring careful experimental design and interpretation:

• Epitope-specific effects: Phosphorylation events near or within the antibody epitope can either enhance or inhibit antibody binding, creating potential false negative or variable detection across cell cycle phases.

• Phosphorylation-specific antibodies: For cell cycle studies where SPCC1235.18 undergoes regulated phosphorylation, developing phospho-specific antibodies against key modified residues provides valuable tools for tracking regulatory events.

• Validation strategies:

• Interpretation guidelines: When phosphorylation affects antibody binding, apparent changes in protein levels may actually reflect modification state changes rather than true expression differences, requiring orthogonal methods to distinguish between these possibilities.

Understanding the relationship between SPCC1235.18 phosphorylation and antibody recognition is essential for accurate interpretation of cell cycle-dependent protein dynamics .

How can SPCC1235.18 antibody be adapted for super-resolution microscopy in yeast cells?

Adapting SPCC1235.18 antibody for super-resolution microscopy in yeast cells requires specific optimizations:

• Fluorophore selection: For STED microscopy, select photostable dyes with appropriate excitation/emission properties like Atto647N or Abberior STAR RED conjugated to secondary antibodies or directly to primary antibodies using site-specific labeling techniques like FluoSite™ .

• Sample preparation modifications:

  • Fixed cell thickness is critical - optimize spheroplasting conditions to reduce thickness below 10 μm

  • Mount samples in specialized media with matched refractive index (1.518) to minimize spherical aberrations

  • Use high-precision (#1.5H) coverslips with thickness tolerance of ±5 μm

• Labeling density optimization: For single-molecule localization microscopy (PALM/STORM), the sparse labeling requirement may necessitate using a mixture of labeled and unlabeled primary antibodies (typical ratio 1:5 to 1:10).

• Multi-color imaging strategies: When combining SPCC1235.18 antibody with other markers, select fluorophores with minimal spectral overlap and implement sequential imaging with appropriate controls for chromatic aberration.

• Validation controls: Include tests for non-specific binding that may only become apparent at super-resolution scales by comparing with knockout strains and competing peptide controls .

What considerations apply when using SPCC1235.18 antibody for quantitative proteomics workflows?

Integrating SPCC1235.18 antibody into quantitative proteomics workflows requires addressing several technical considerations:

• Immunoprecipitation optimization for MS compatibility:

  • Minimize detergent use or select MS-compatible detergents (Rapigest, ProteaseMAX)

  • Implement stringent washing protocols to reduce co-purifying background proteins

  • Consider cross-linking antibodies to beads to prevent antibody contamination in the sample

• Protocol adjustments for different quantitative approaches:

• Controls for MS data interpretation:

  • Implement matched IgG controls to identify non-specific binding proteins

  • Include spike-in standards to normalize across samples

  • Compare immunoprecipitation efficiency across samples using Western blotting

• Data analysis considerations:

  • Account for sample-specific background binding patterns

  • Implement appropriate statistical methods for discriminating specific from non-specific interactions

  • Validate key findings using orthogonal methods (reciprocal IP, proximity labeling)

These adaptations enable the integration of antibody-based enrichment with the sensitivity and comprehensiveness of mass spectrometry-based proteomics .

How can computational modeling guide SPCC1235.18 antibody engineering for improved research applications?

Computational modeling provides powerful approaches for engineering SPCC1235.18 antibodies with enhanced research capabilities:

• Epitope prediction and optimization:

  • Structure-based epitope prediction identifies optimal regions for antibody generation

  • Molecular dynamics simulations assess epitope accessibility in different protein conformations

  • Machine learning algorithms can predict immunogenicity and cross-reactivity risks

• Antibody modeling approaches:

  • Canonical structure-based modeling predicts CDR conformations based on sequence

  • Framework region analysis identifies residues critical for stability versus those amenable to mutation

  • Molecular docking simulations evaluate potential antigen-antibody interfaces

• Affinity optimization strategy:

  • In silico mutagenesis identifies key residues for targeted modification

  • Free energy calculations prioritize mutations likely to enhance binding without compromising specificity

  • Rational library design focuses experimental efforts on most promising candidates

• Implementation workflow:

• Experimental validation planning:

  • Design of minimal variant sets to test computational predictions

  • Benchmark computational predictions against experimental outcomes

  • Iterative refinement of computational models based on experimental results

This integrated computational-experimental approach accelerates the development of SPCC1235.18 antibodies with optimal research characteristics while minimizing resources required for extensive screening campaigns .

How are machine learning approaches improving SPCC1235.18 antibody validation workflows?

Machine learning is transforming antibody validation workflows for research reagents like SPCC1235.18 antibody:

• Automated image analysis for specificity testing:

  • Deep learning algorithms can classify staining patterns in immunofluorescence images

  • Convolutional neural networks detect subtle differences between specific and non-specific signals

  • Transfer learning approaches enable application across different experimental conditions

• Predictive models for cross-reactivity:

  • Sequence-based algorithms identify potential cross-reactive proteins

  • Feature extraction from epitope sequences improves prediction accuracy

  • Ensemble methods combine multiple predictors for robust cross-reactivity assessment

• Application-specific performance prediction:

  • Random forest models predict antibody performance across different applications

  • Bayesian inference estimates probability of successful application transfer

  • Active learning approaches guide optimal validation experiment selection

• Quality control enhancement:

  • Anomaly detection identifies inconsistent antibody performance

  • Time series analysis tracks antibody stability and lot-to-lot variation

  • Pattern recognition in validation data flags potential specificity concerns

These computational approaches complement traditional validation methods, improving efficiency and robustness of antibody characterization while reducing resource requirements and experimental biases .

What are the latest advances in SPCC1235.18 antibody formats for specialized research applications?

Recent advances in antibody engineering have created new formats that expand the research utility of antibodies like those targeting SPCC1235.18:

• Single-domain antibodies (nanobodies):

  • Derived from camelid heavy-chain-only antibodies

  • Enhanced penetration into protein complexes due to smaller size (~15 kDa)

  • Improved access to sterically hindered epitopes in crowded cellular environments

  • Superior performance in super-resolution microscopy applications

• Bispecific antibody formats:

  • Simultaneous targeting of SPCC1235.18 and interaction partners

  • Improved co-localization studies and protein proximity analysis

  • Enhanced signal amplification for detection of low-abundance targets

  • Available as various formats including diabodies, tandem scFvs, and dual-variable domain antibodies

• Site-specifically conjugated antibodies:

  • Precise control over conjugation site location away from antigen-binding domains

  • Homogeneous labeled antibody preparations with consistent performance

  • Enhanced sensitivity in flow cytometry and fluorescence microscopy applications

  • Technologies like FluoSite™ enable reproducible and oriented labeling

• Recombinant antibody fragments:

  • Fab, scFv, and other formats with reduced size and improved tissue penetration

  • Amenable to bacterial expression systems for cost-effective production

  • Modular design enabling fusion to various detection and targeting moieties

  • Reduced background from Fc-mediated interactions

These innovative formats expand the experimental capabilities of SPCC1235.18-targeting antibodies for specialized research applications requiring enhanced penetration, multiplexing, or precise molecular targeting .

What resources are available for validating novel SPCC1235.18 antibody preparations?

Researchers developing or validating SPCC1235.18 antibodies can access several resources:

• Reference materials:

  • Recombinant SPCC1235.18 protein standards for specificity testing

  • Pre-immune serum as negative control for establishing baseline binding

  • Synthetic peptide fragments covering distinct epitope regions

• Genetic resources:

  • SPCC1235.18 deletion strains from yeast knockout collections

  • Strains expressing epitope-tagged versions for parallel validation

  • Temperature-sensitive mutants for conditional expression

• Computational tools:

  • Epitope prediction algorithms (BepiPred, DiscoTope)

  • Antibody modeling platforms (http://dunbrack2.fccc.edu/PyIgClassify/)[1]

  • Cross-reactivity prediction software for specificity assessment

• Protocol repositories:

  • Optimized immunoprecipitation protocols for yeast proteins

  • Application-specific troubleshooting guides

  • Standardized validation workflows based on antibody reporting standards

These resources collectively support comprehensive validation of SPCC1235.18 antibodies according to best practices in antibody characterization for research applications .

How should researchers interpret conflicting results between different lots of SPCC1235.18 antibody?

When researchers encounter conflicting results between different lots of SPCC1235.18 antibody, a systematic analysis approach is recommended:

• Documentation review:

  • Compare lot-specific validation data from manufacturers

  • Examine differences in immunogen sequence, production method, and purification approach

  • Review lot-specific quality control metrics and acceptance criteria

• Systematic comparison testing:

  • Perform side-by-side testing under identical conditions

  • Include positive and negative controls for each lot

  • Test across multiple applications to identify pattern of differences

• Root cause analysis:

• Experimental design adaptation:

  • Include lot-specific calibration controls in experiments

  • Avoid mixing lots within experimental series

  • Document lot information in publications to support reproducibility